On March 12, 2019 IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company reported that members of the Company’s research and development team will present results from a study at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2019, which is being held March 29 to April 3 in Atlanta, Georgia (Press release, IMV, MAR 12, 2019, View Source [SID1234534242]). The new preclinical research highlights the unique features of DPX-based T cell immunotherapies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The unique capabilities of our DPX-based platform and its potential to fuel novel treatment approaches continue to drive IMV’s robust research and development program"

Tweet this
"The unique capabilities of our DPX-based platform and its potential to fuel novel treatment approaches continue to drive IMV’s robust research and development program," said Marianne Stanford, PhD, Vice President, Research and Development of IMV. "We are looking forward to presenting additional insights into the way our platform works, and its capacity for working with other anti-cancer agents, at this year’s AACR (Free AACR Whitepaper) annual meeting. This work supports our goal of expanding the benefits of immunotherapies to a wider range of patients and indications."

Details of IMV’s AACR (Free AACR Whitepaper) 2019 poster is as follows:

Session Category: Immunology
Abstract Number: 4989
Authors: Ava Vila-Leahey, Alecia MacKay, Genevieve Weir, Marianne Stanford

Title: T-distributed stochastic neighbor embedding (t-SNE) analysis of tumor infiltrating lymphocytes after treatment with a T cell activating therapy identifies a unique population of recruited CD8+ T cells and novel options for combination immunotherapy

Date: Wednesday Apr 3, 2019
Time: 8:00 a.m. – 12:00 p.m. ET
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 24
Poster Board Number: 12

Meeting abstracts are available at AACR (Free AACR Whitepaper)’s website.

On March 12, 2019 CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, reported that management will participate in four investor conferences in March, including the 31st Annual ROTH Conference in Laguna Niguel, California, the Oppenheimer 29th Annual Healthcare Conference in New York City, the Oppenheimer’s Biotech Summit by the Lake at Northwestern University in Evanston, Illinois, and the ROTH Battle of NASH Thrones Spring Investor Conference in New York City (Press release, CymaBay Therapeutics, MAR 12, 2019, View Source [SID1234534243]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

31st Annual ROTH Conference
Date: Monday, March 18
Time: 9:30am Pacific Time
Format: Panelist: Why Knowing NASH as a Generalist Can Make You Rich in 2019

Time: 12:00pm Pacific Time
Format: Fireside Chat
Webcast: View Source

Oppenheimer 29th Annual Healthcare Conference
Date: Tuesday, March 19
Time: 8:35am Eastern Time
Format: Fireside Chat
Webcast: View Source

Oppenheimer’s Biotech Summit by the Lake
Date: Wednesday, March 27
Time: 1:00pm Central Time
Format: Corporate Presentation

ROTH Battle of NASH Thrones Spring Investor Conference
Date: Thursday, March 28
Time: 8:00 am Eastern Time
Format: Panel: 12 Months of Data – 2019 Is the Year for FXR and PPAR Clinical Readouts

Time: 4:00pm Eastern Time
Format: Panel: Why MRI May Hold the Key to the Kingdom in Diagnosis and Drug Development

On March 12, 2019 DiaMedica Therapeutics Inc. (Nasdaq: DMAC) reported that it will be attending the 31st Annual ROTH Conference March 18-19, 2019, at The Ritz Carlton, Laguna Niguel in Dana Point, CA (Press release, DiaMedica, MAR 12, 2019, View Source [SID1234534285]). DiaMedica’s President and CEO, Rick Pauls, will be hosting one-on-one meetings with institutional investors at the conference and attendees can contact their Roth Capital Partners representative to arrange a meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 11, 2019 Yuhan Corporation (000100.KS; Yuhan) and Sorrento Therapeutics, Inc. (Nasdaq: SRNE) announced today that ImmuneOncia, a joint venture formed in September 2016, has completed the Phase 1 study of IMC-001 (also known as STI-3031), a fully human anti-PD-L1 monoclonal antibody (mAb) immune checkpoint inhibitor (Press release, Sorrento Therapeutics, MAR 11, 2019, View Source [SID1234534199]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This Phase 1 dose-escalation study, approved by the South Korean Ministry of Food and Drug Safety (MFDS) in February of 2018, enrolled subjects with locally-advanced or metastatic solid tumors at Seoul National University Hospital (SNUH) and Samsung Medical Center (SMC). The Recommended Phase 2 Dose (RP2D) was determined to be successful with no observations of dose-limiting toxicities. More results of this study will be disseminated at upcoming conferences.

"Based on the results of the Phase 1 trial of IMC-001, we are planning on conducting a Phase 2 trial to evaluate its efficacy in rare cancers in the second half of this year," stated Yun Jeong Song, CEO of ImmuneOncia. "Moreover, we greatly appreciate those who supported us and for their contributions as the company successfully completed a Phase 1 trial of IMC-001. In collaboration with various institutions, we will continue our research and development of IMC-001 as well as the additional checkpoint immune-oncology molecules in our pipeline."

About IMC-001 (PD-L1 monoclonal antibody)

IMC-001 is a fully human anti-PD-L1 monoclonal antibody immune checkpoint inhibitor. The mAb blocks the interaction of PD-L1 protein with its receptor PD-1, suppressing the inhibitory signal to T cells and enhancing the killing effect of T cells on tumors. This antibody also kills cancer cells through traditional antibody-dependent cell-mediated cytotoxicity (ADCC) recruiting natural killer (NK) cells and other effector cells against the tumor and potentially further strengthening the anti-tumor effect of the antibody. The clinical-grade material of IMC-001 was manufactured by Sorrento in its San Diego-based GMP antibody production facility.

On March 11, 2019 Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, reported two poster presentations at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting being held March 29 – April 3, 2019 in Atlanta, Georgia (Press release, Advaxis, MAR 11, 2019, View Source [SID1234534226]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation 1
Title: Safety and immunogenicity of a personalized neoantigen-Listeria vaccine in cancer patients
Presenter: J. Randolph Hecht M.D., UCLA
Session: Phase I Clinical Trials: Part 1
Abstract Number: CT007
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 16
Date and Time: Sunday, March 31, 2019 1:00 p.m. – 5:00 p.m. ET

Poster Presentation 2
Title: KEYNOTE-046: Effects of ADXS-PSA with or without pembrolizumab on survival and antigen spreading in metastatic, castration-resistant prostate cancer patients
Presenter: Mark N. Stein M.D., FACS, Columbia University, NYC
Session: Phase I Clinical Trials: Part 3
Abstract Number: CT098
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 16
Date and Time: Monday, April 1, 2019 1:00 p.m. – 5:00 p.m. ET

All accepted abstracts will be published in the 2019 Proceedings of the AACR (Free AACR Whitepaper). Session information is available online via the Annual Meeting Itinerary Planner through the AACR (Free AACR Whitepaper) website at www.aacr.org.